112 related articles for article (PubMed ID: 34127243)
1. Cost-effectiveness analysis with unordered decisions.
Díez FJ; Luque M; Arias M; Pérez-Martín J
Artif Intell Med; 2021 Jul; 117():102064. PubMed ID: 34127243
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness Analysis with Influence Diagrams.
Arias M; Díez FJ
Methods Inf Med; 2015; 54(4):353-8. PubMed ID: 25762363
[TBL] [Abstract][Full Text] [Related]
3. Markov Influence Diagrams.
Díez FJ; Yebra M; Bermejo I; Palacios-Alonso MA; Calleja MA; Luque M; Pérez-Martín J
Med Decis Making; 2017 Feb; 37(2):183-195. PubMed ID: 28076183
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Use of influence diagrams to structure medical decisions.
Nease RF; Owens DK
Med Decis Making; 1997; 17(3):263-75. PubMed ID: 9219186
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
12. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
13. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Sarker SJ; Whitehead A; Khan I
Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
[TBL] [Abstract][Full Text] [Related]
15. Representation and analysis of medical decision problems with influence diagrams.
Owens DK; Shachter RD; Nease RF
Med Decis Making; 1997; 17(3):241-62. PubMed ID: 9219185
[TBL] [Abstract][Full Text] [Related]
16. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
Nelson RE; Stenehjem D; Akerley W
Lung Cancer; 2013 Dec; 82(3):461-8. PubMed ID: 24074609
[TBL] [Abstract][Full Text] [Related]
17. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis when the WTA is greater than the WTP.
Willan AR; O'Brien BJ; Leyva RA
Stat Med; 2001 Nov; 20(21):3251-9. PubMed ID: 11746316
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model.
Whiting P; Westwood M; Bojke L; Palmer S; Richardson G; Cooper J; Watt I; Glanville J; Sculpher M; Kleijnen J
Health Technol Assess; 2006 Oct; 10(36):iii-iv, xi-xiii, 1-154. PubMed ID: 17014747
[TBL] [Abstract][Full Text] [Related]
20. PGMC: a framework for probabilistic graphic model combination.
Jiang CA; Leong TY; Poh KL
AMIA Annu Symp Proc; 2005; 2005():370-4. PubMed ID: 16779064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
